Ho
Horizon (Amgen)
Dublin IEFounded 20054,200 employees
Private CapbiotechAcquiredRare DiseaseImmunology
Platform: Tepezza
Market Cap
N/A
All Drugs
3
Clinical Trials
7
Failed / Terminated
4
FDA Approved
0
Drug Pipeline (3 programs)
| Drug Name | Code | Phase | Trials | Modality | Target | MOA | Indications |
|---|---|---|---|---|---|---|---|
| HOR-3601 | HOR-3601 | Phase 1/2 | 2 | FXIa | CLLThymoma | ||
| HOR-3482 | HOR-3482 | Phase 3 | 4 | MET | SMAPsoriasis | ||
| Suraosocimab | HOR-1002 | Phase 1 | 1 | PSMA | FSGSNB |
Financial Documents
This company has been acquired — see parent company for financial filings.
Catalyst Events (9)